Results for tag: "Hematologic Malignancy Drug"

The Hematologic Malignancy Drug market is a subset of the Oncology Drugs market, which focuses on the treatment of blood cancers such as leukemia, lymphoma, and myeloma. These drugs are used to treat both acute and chronic forms of these diseases, and can be administered orally, intravenously, or subcutaneously. Common drugs used in this market include chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. The Hematologic Malignancy Drug market is highly competitive, with many large pharmaceutical companies vying for market share. Companies in this market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more